In our latest M3 Pulse survey, 2400 physicians reported their level of concern about the potential impact of new healthcare tariffs on healthcare costs, medical supplies, and services in their country. View the full results here.
Recent U.S. trade proposals include potential tariffs on imported materials vital to healthcare, such as active pharmaceutical ingredients (APIs), medical devices, and supplies, though finished drugs remain mostly exempt for now. This raises concerns about rising costs and global supply chain disruptions.
With global pharmaceutical supply chains interconnected, new U.S. tariffs risk triggering worldwide ripple effects. Countries heavily reliant on Chinese and Indian API exports, including those in Europe, Latin America, and Africa, may face cascading drug shortages, production delays, and rising healthcare costs.
Manufacturers across the globe are grappling with financial and regulatory challenges as they consider reshoring or diversifying supply chains. Industry bodies are calling for multilateral cooperation, expanded tariff exemptions, and cross-border investment in resilient pharmaceutical infrastructure to ensure global supply stability and affordability.
Continue reading to learn more about healthcare tariffs and the survey results:
What do you think about the new tariffs and the potential impact on healthcare costs and patient care as a healthcare professional? Please share your thoughts in the comments section below.
What is a Tariff in Healthcare?
A tariff is a tax imposed on goods as they cross international borders. In the context of healthcare, tariffs typically apply to imported pharmaceutical ingredients, medical devices, hospital equipment, and other healthcare supplies. These taxes raise the cost of imports, which can ripple through the system, leading to higher prices for hospitals, clinics, insurers, and most importantly, patients.
Since April 2025, the U.S. has imposed sweeping tariffs on healthcare imports, 10% on most goods, 25% on nonUSMCA medical devices, and up to 245% on active pharmaceutical ingredients (APIs) from China.* While aimed at boosting domestic production and supply-chain resilience, these tariffs can carry significant cost implications.
A Reuters commissioned report by Ernst & Young estimates a 25% tariff on pharmaceutical imports could add nearly $51 billion to annual U.S. drug expenses, a potential 12.9% rise in prices if fully passed to consumers.* In the short term, manufacturers may initially absorb costs, but analysts warn that small margin generic producers will be hit hardest and drugmakers could eventually scale back R&D and staffing.
On the global stage, countries like China have exempted key medicines but retaliated with 34% tariffs on U.S. goods.* In the U.K., economic growth contracted by 0.3% in April, its steepest monthly decline since late 2023, with analysts attributing part of the slump to U.S. tariff disruption in exports, including medical technology.*
For healthcare professionals worldwide, these tariff shifts aren’t abstract trade policy, they directly influence procurement costs, device availability, and patient treatment options. Staying informed is essential for advocacy, budgeting, and strategic planning as the landscape evolves.
M3 Pulse Results: How Do Physicians Feel About Increased Healthcare Tariffs?
In a recent M3 Pulse survey, 2400 physicians from around the world, including 677 respondents from the United States, were asked how concerned they are about the potential impact of international trade policies and tariffs on the cost and availability of medical supplies, medications, and healthcare services in their country.
Key Insights:
- Nearly two-thirds of physicians (62%) expressed high levels of concern, highlighting fears of supply chain disruptions and rising healthcare costs, particularly for essential items like generics and medical equipment.
- A smaller portion (12%) said they were minimally or not concerned, viewing tariffs as part of a necessary economic strategy that would not significantly affect healthcare delivery.
- Only 0.4% voiced clear support for tariffs, suggesting limited optimism about the long-term benefits outweighing short-term disruption among healthcare professionals (answers not including U.S respondents).
*Please select your language
/>
M3 Pulse is a one-question online survey we conduct every month with our M3 panel members. It´s a fun and easy way to share your opinions about trending healthcare topics, like the shortage of physicians, with healthcare professionals worldwide. If you want to participate in this month´s M3 Pulse, register and join the M3 panel today.
These results suggest a strong current of concern among global physicians regarding the potential consequences of the new tariffs for patient care and system stability.
Potential Impact of Tariffs on Healthcare Costs and Supply
The introduction of tariffs on medical imports can have both positive and negative implications for healthcare systems. On one hand, tariffs are designed to encourage domestic manufacturing, strengthen supply chain resilience, and reduce long-term reliance on foreign suppliers. In theory, this could lead to greater national control over essential medical goods, increased local employment, and more predictable access during times of global disruption.
However, the short- to medium-term effects often include higher costs for imported medical devices, pharmaceutical ingredients, and other essential healthcare supplies. These increased costs may be absorbed by manufacturers, passed on to hospitals and clinics, or eventually reflected in insurance premiums and patient expenses. For providers working with fixed budgets, this can create pressure on procurement decisions and resource allocation.
Tariffs may also impact availability. Complex global supply chains mean many medical products rely on components sourced internationally. When tariffs are applied at different stages of production, delays or shortages can occur, particularly for generic medicines and high-precision equipment.
From an industry perspective, companies may respond by shifting production domestically, seeking alternative suppliers, or re-evaluating market priorities. While this can foster local growth, it may also limit access to certain products in smaller or lower-margin markets.
For healthcare professionals and systems worldwide, the effects of tariffs will depend on factors such as local production capacity, regulatory flexibility, and the extent to which governments implement mitigating policies. Some may experience strengthened supply chains and industrial growth, while others face higher costs or reduced availability in the short term.
In a globalised healthcare landscape, tariffs are a significant policy lever. Their impact is complex and context-dependent—balancing national economic goals with the practical realities of delivering timely, affordable, and high-quality care.
Let us know what you think about new tariffs and healthcare costs in the comment section below.
Join the M3 Panel
Would you like to be rewarded for your medical expertise? Join M3 today and share your opinion
More M3 Pulse:
Climate Change and Health: A New Era of Clinical Challenges
Climate change and health drive shifts in disease patterns, increasing climate-related health risks and pressure on healthcare systems.
Beyond Infectious Diseases: How mRNA Technology Could Transform Global Health
The Lancet highlights how mRNA Technology is advancing vaccines, cardiovascular disease treatment, and mRNA cancer vaccines.
